Corcept Therapeutics Incorporated Book Value 2011-2026 | CORT

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Corcept Therapeutics Incorporated

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
680 M	507 M	502 M	376 M	523 M	371 M	276 M	191 M	41.4 M	18.5 M	-3.39 M	21 M	61.8 M	34.8 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
680 M	-3.39 M	257 M

Quarterly Book Value Corcept Therapeutics Incorporated

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
632 M	636 M	683 M	639 M	596 M	548 M	462 M	422 M	530 M	-	473 M	-	408 M	376 M	540 M	523 M	511 M	523 M	523 M	523 M	523 M	371 M	371 M	371 M	371 M	276 M	276 M	276 M	276 M	191 M	221 M	221 M	221 M	68.8 M	68.8 M	68.8 M	68.8 M	51.9 M	51.9 M	51.9 M	51.9 M	34.6 M	34.6 M	34.6 M	34.6 M	63.1 M	63.1 M	63.1 M	63.1 M	99.2 M	99.2 M	99.2 M	99.2 M	39.8 M	39.8 M	39.8 M	39.8 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
683 M	34.6 M	272 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Adaptive Biotechnologies Corporation ADPT	202 M	$ 18.36	-0.78 %	$ 2.7 B	USA
Amgen AMGN	91.8 B	$ 343.69	0.53 %	$ 185 B	USA
Arrowhead Pharmaceuticals ARWR	1.39 B	$ 70.78	2.09 %	$ 9.47 B	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Aytu BioScience AYTU	124 M	$ 2.66	2.31 %	$ 16.7 M	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Adagene ADAG	50.5 M	$ 2.97	8.0 %	$ 167 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.14	-0.95 %	$ 7.55 B	Australia
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Biogen BIIB	16.7 B	$ 179.14	-0.42 %	$ 26.1 B	USA
Aeglea BioTherapeutics AGLE	518 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	-30.6 M	$ 1.41	-0.35 %	$ 264 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Ascendis Pharma A/S ASND	-106 M	$ 223.85	-1.0 %	$ 5 B	Danmark
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Burford Capital Limited BUR	1.66 B	$ 9.82	1.34 %	$ 1.59 B	Britain
BioNTech SE BNTX	19.4 B	$ 110.32	-3.02 %	$ 27.2 B	Germany
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Autolus Therapeutics plc AUTL	427 M	$ 1.39	1.09 %	$ 355 M	Britain
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Cardiff Oncology CRDF	82.9 M	$ 1.72	-1.71 %	$ 82 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 4.13	2.99 %	$ 8.99 B	Israel
Adaptimmune Therapeutics plc ADAP	39.5 M	-	-15.15 %	$ 60.3 M	Britain
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Amneal Pharmaceuticals AMRX	3.5 B	$ 14.13	3.25 %	$ 4.37 B	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
BioCryst Pharmaceuticals BCRX	-476 M	$ 6.69	1.6 %	$ 1.38 B	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Beam Therapeutics BEAM	734 M	$ 27.78	0.58 %	$ 2.29 B	USA
BeiGene, Ltd. BGNE	3.33 B	-	0.49 %	$ 251 B	Cayman-islands
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel